## Page 1

SPECIAL ARTICLE
Novel psychoactive substances of interest
for psychiatry
FABRIZIOSCHIFANO 1, LAURA ORSOLINI 1,2, G.DUCCIOPAPANTI 1,3,JOHNM. CORKERY 1
1SchoolofLifeandMedicalSciences,UniversityofHertfordshire,Hatfield,Herts,UK;2UnitedHospitalandAcademicDepartmentofExperimentalandClinical
Medicine,PolytechnicUniversityofMarche,Ancona,Italy;3MedicalSchool,UniversityofTrieste,Trieste,Italy
Novelpsychoactivesubstancesincludesyntheticcannabinoids,cathinonederivatives,psychedelicphenethylamines,novelstimulants,synthetic
opioids,tryptaminederivatives,phencyclidine-likedissociatives,piperazines,GABA-A/Breceptoragonists,arangeofprescribedmedications,psy-
choactiveplants/herbs,andalargeseriesofperformanceandimageenhancingdrugs.Usersaretypicallyattractedbythesesubstancesduetotheir
intensepsychoactiveeffectsandlikelylackofdetectioninroutinedrugscreenings.Thispaperaimsatprovidingpsychiatristswithupdatedknowl-
edgeoftheclinicalpharmacologyandpsychopathologicalconsequencesoftheuseofthesesubstances.Indeed,thesedrugsactonarangeofneuro-
transmitter pathways/receptors whose imbalance has been associated with psychopathological conditions, including dopamine, cannabinoid
CB1,GABA-A/B,5-HT2A,glutamate,andkopioidreceptors.Anoverallapproachintermsofclinicalmanagementisbrieflydiscussed.
Keywords:Novelpsychoactivesubstances,legalhighs,smartdrugs,researchchemicals,substanceabuse,dualdiagnosis,psychedelicphen-
ethylamines,syntheticcannabimimetics,phencyclidine-likedrugs,cathinones,tryptamines
(WorldPsychiatry2015;14:15–26)
In parallel with a decrease/stabilization of the use of SYNTHETICCANNABIMIMETICS
internationally controlled drugs (1), the market of novel
psychoactive substances is on the rise year on year. The Synthetic cannabimimetic (SC) preparations are com-
diffusion of these substances has been identified in 94 posed by a dried plant,marijuana-like, baseand a sprayed
countries/territories (2), with some 5% of 19-24 years old mixture of SCs. Oral/e-liquid/injectable SC formulations
European people having already experimented with them. are also available (10-12). Within any given “Spice” pack-
Thewebplaysamajorroleinshapingthisunregulatedmar- age, usually a range of different SC molecules (13) and/
ket(3),withusersbeingattractedbythesesubstancesdueto orfurtherpsychoactives(14-20)canbeidentified.Batches
both their intense psychoactive effects and likely lack of ofthesamebrandmaypossesshighlyvariableSCconcen-
detectioninroutinedrugscreenings(4). trations(21).
Overall, novel psychoactive substances are defined as ItislikelythatafewhundredsofSCmoleculesarecur-
newnarcotic/psychotropic drugswhicharenotcontrolled rently available (8,9). SCs possess high/very high cannabi-
bytheUnitedNations’1961NarcoticDrugs/1971Psycho- noid receptor binding affinity levels, with a significantly
tropicSubstancesConventions,butwhichmayposeapub- higher dose-response efficacy than tetrahydrocannabinol
lic health threat (5).However, “novel” willnotnecessarily itself (22,23). In addition to this, some SCs show further
meanhereanewdevelopment,butwillrefertosubstances pharmacodynamicactions(24)whichmaypersebearea-
thathaverecentlybecomepopular/available,constitutinga son of clinical concern, such as N-methyl-D-aspartate
reasonofcurrent/potentialpublichealthconcern. (NMDA) receptor antagonism (25) and/or monoamine
Inparticular,thereareincreasinglevelsofconcernabout oxidase (MAO) inhibitory properties (26). Furthermore,
the onset of acute/chronic psychopathological manifesta- almostallSCspossessindole-derivedstructures,whichmay
tionsassociatedwiththeintakeofarangeofnovelpsycho- in itself facilitate 5-HT2A receptor dysfunction, typically
active substances (3,6,7). Here we provide an overview of associated with both hallucinations/psychosis (27-30) and
the clinical pharmacology of the few hundred substances the serotonin syndrome (31). Further, the recent trend of
available (4,8,9) and the psychopathological disturbances SC fluorination may increase the compounds’ lipophilicity,
theycanproduce. hence enhancing the absorption through biological mem-
WesearchedMedline/PubMedforstudiesusingtheterms branes/bloodbrainbarrier(32,33).
“new psychoactive substances”, “novel psychoactive sub- AcuteSCintoxicationischaracterizedbyagitation/anxi-
stances”, “legal highs”, “designer drugs”, “research chem- ety and visual/auditory hallucinations (34-36), together
icals”,“smartdrugs”,and“emergingdrugsofabuse”.Asimi- withtachycardia,hypertension,mydriasis,hyperglycaemia,
larsearchwascarriedoutforthemaingroupsofsubstances dyspnoea,vomitingandseizures.FurtherSC-relatedmedi-
and associated psychiatric manifestations. Where no infor- cal complications may include stroke, encephalopathy,
mation relating to the index substances was available from myocardialinfarctionandacutekidneyinjuries(37-40).
thepeerreviewedliterature,specificwebsiteswereidentified A number of analytically confirmed accidental deaths/
by typing the index substance keywords on Google, with suicides have been related to SC ingestion, either on their
selectionandanalysisofforaposts/threads. own or in combination with other compounds (41-51).
15

## Page 2

Long-term SC misuse may be associated with both toler- 2,5-dimethoxy-4-bromophenethylamine (2-CB, “Nexus”)
ance/dependence (35,52) and a severe/prolonged with- (68),2,5-dimethoxy-4-iodophenethylamine(2C-I)(69),and
drawalsyndrome(53-56).Ariskofdevelopingpsychosisin 2,5-dimethoxy-4-ethylphenethylamine (2C-E) (70). Most
chronicmarijuanausershasrepeatedlybeendescribed,and 2Cdrugsshowaffinityfor5-HT2Areceptors,whilstsomeof
a correlation with the dosage ingested has been reported them inhibit the dopamine/noradrenaline/serotonin reup-
(57). Similarly, SC intake has been associated with the takeaswell(3).Theymay bepurposefullyorunintention-
occurrence of florid/acute transient psychosis, relapse/ allyingestedasMDMAsubstitutes.
worsening of a pre-existing psychosis, persisting psychotic With MDMA-like drugs, enhanced mood, increased
disorders/“spiceophrenia”(6),andmanic-likesymptomsor energy, openness and perceptual alterations are typically
relapseofpre-existingbipolardisorder(58,59). reported,togetherwitharangeofserotonergicandsympa-
thomimetic toxicity effects, including tachycardia, hyper-
tension,metabolicacidosis,convulsions,rhabdomyolysis,
SYNTHETICCATHINONES mydriasis, vomiting, diarrhoea and thrombocytopenia.
Acuterenalfailureandhyperthermiaareareasonofpar-
Synthetic cathinones have been first detected by our ticularconcern(3,7,71,72).
web-mapping research group in 2008 (4). They are beta- 3C-bromo-Dragonfly (“B-Fly”) has been described as a
ketophenethylaminesstructurallysimilartoamphetamines/ powerful/longlasting(upto3daysofpsychoactiveeffects)
catecholamines, with subtle variations that alter their drug, associated with long-standing hallucinations, mood
chemicalproperties,potency,pharmacokineticsandphar- elevation, paranoid ideation, confusion, anxiety and flash-
macodynamics.Theirpopularitywasdrivenbythelackof backs(73).
availabilityorthepoorpurityofcocaineor3,4-methylene- 25C-NBOMe (“N-bomb”, “Pandora”) (74) isone of the
dioxy-methamphetamine (MDMA, “Ecstasy”), combined mostpopularNBOMecompounds,agroupofhighpotency
withlittle,ifany,legalrestrictions(3). drugswhicharecurrentlyareasonofpublichealthconcern
Typically, synthetic cathinones are snorted or ingested (8,9).Soldonlineaslegallysergicacidandtypicallyingested
orally or injected. For mephedrone, the half-life is as orally or sublingually, “N-bomb” is a partial agonist of
shortasonehour,hencethere-dosingrisk(60).Eachsyn- 5-HT2Areceptors.Itseffectsincludestimulation,hallucina-
thetic cathinone has variable effects and potency levels tions, dissociation, anxiety, aggression and unpredictable
on serotonin, dopamine and noradrenaline pathways, but violentepisodes(74).
all typically possess sympathomimetic/amphetamine-like “B-Fly”, “N-bomb”, para-methoxyamphetamine (PMA,
effects(8,9). “Dr.Death”),4-methyltioamphetamine(4-MTA,“flatliners”)
Cathinone-relatedpsychoactiveeffectsincludeincreased and 6-(2-aminopropyl) benzofuran (6-APB, “Benzofury”)
alertness, euphoria, excited delirium, hallucinations, agita- haveallbeenimplicatedinanumberofacutetoxicityevents
tionandaggression,associatedwithtachycardia,hyperten- and fatalities (47,73,74).
sionanddilatedpupils.Abdominalpain,flushing,sweating,
chills, restlessness and anxiety can be observed as well
(8,9,61). Mood disturbances and paranoid ideation have NOVELSTIMULANTS
beenobservedinchronicusers(61-64).Additionalreported
mephedrone serious effects include hyperthermia, rhabdo- 4,4’-dimethylaminorex (4,4’-DMAR, “Serotoni”) is a
myolysis,renalfailureandseizures. derivativeofaminorex(75,76)whichhasbeenassociatedin
Fatalities have been associated with mephedrone 2013/2014withsome30deathsinEurope(77).Similarto
(47,61,62),methyloneandbutylone(65).Asignificantpro- amphetamine-type stimulants (71), “Serotoni” is a potent
portion of synthetic cathinones’ users report tolerance, dopamine/noradrenalinereleaserwhilstinhibitingthesero-
dependenceorwithdrawalsymptoms(66).Abstinentmeth- tonintransporteraswell(78).Itmaybesnortedoringested
cathinone users may present with decreased striatal dopa- (79-81). It produces euphoria, alertness and agitation last-
minetransporterdensityonpositronemissiontomography ingseveralhours(80).Hyperthermiaandcardiorespiratory
scans,suggestingthepotentialriskforlong-termpsychiatric problemshavealsobeendescribed(82).
problems(67). Althoughsynthesizedsome70yearsago,methiopropamine
(MPA,“Blow”),amethamphetamineanalogue,startedtobe
recentlyadvertisedonlineasa“researchchemical”(83-85)to
NOVELDERIVATIVESOF“CLASSICAL”PSYCHEDELIC besmoked,ingestedorsnorted.Beingaselectivenoradrena-
PHENETHYLAMINES/MDMA-LIKEDRUGS line/dopaminereuptakeinhibitor(86),itproduceseuphoria,
hallucinations, alertness and sexual arousal. This may be
MDMA(“Ecstasy”)isonlyoneofthepsychedelicphene- associatedwithlossofappetite,tachycardia,anxiety,nau-
thylamine products. Recent and popular appearances into sea,headache,dizziness,skinirritation,difficultyurinating
the drug scenario include a few 2C molecules, such as andhangovereffects(87).
16 WorldPsychiatry14:1-February2015

## Page 3

SYNTHETICOPIOIDS detected in humans as well (107-109), even though their
biologicalfunctionsremainunclear.
These compounds share with morphine most of their Thepredominantclinicaleffectsoftryptamines,associat-
clinical pharmacological effects, including analgesia, seda- ed with both agonist activities at 5-HT2A receptors and
tion,euphoriaandriskofrespiratorydepression. serotonintransporterinhibition(110-117),consistinvisual
AH-7921 (“doxylam”) is equipotent to morphine (88). hallucinations,alterationsinsensoryperception,distortion
Althoughfirstsynthesizedsome45yearsago,itisnowavail- ofbodyimage,depersonalization,markedmoodlabilityand
ableonlineinpowderformtobesnortedoringested.Afew anxiety/panic(98,118).Untowardeffectsincludeagitation,
relatedfatalitieshaverecentlybeenidentified(82). tachyarrhythmia and hyperpyrexia (111). There are small
Althoughnevermarketedassuch,MT-45wasdeveloped numbers of confirmed post-mortem toxicology reports on
in the early 1970s as a potential analogue of the analgesic tryptamines,mainlyrelatingtoAMT(47).
lefetamine (89). Being a mu/delta/sigma opioid receptor Bufotenin(119)isfoundontheskinofvariousspeciesof
agonist (90), itiscurrently apopular compound, eitheron thetoadBufogenus,inAmanitamushrooms,andinAnade-
its own or in combination with synthetic cathinones nanthera peregrina/Piptoderma peregrina plants (120). Its
(“Wow”)(82).MT-45intakehasbeenassociatedwithrespi- psychoactiveeffectsaremainlyduetoitsenzymaticconver-
ratorydepression,lossofconsciousnessandototoxicity(91) sionto5-MeO-DMT.Typically,consumerssmokethecrystals
andanumberoffatalitiesaswell(82). obtainedby drying theliquidtakenfromthefrogs,but both
Further popular drugs include nortilidine, which is an oralandintravenoususehavebeenrecentlyreportedaswell.
NMDA receptor antagonist and dopamine reuptake inhi- AMT is available mainly from the web, in tablet and
bitor equipotent to morphine (92); the high potency liquidformulations.Visualillusionsandeuphoriahavebeen
mu-opioid agonists W15 and W18 (93); 4-fluoro-butyr- reported(121).5-MeO-AMTand5-MeO-DMThaveastruc-
fentanyl(“4FBF”)andIC-26(“methiodone”),amethadone turesimilartoamphetamine,henceexplainingtheirsympa-
analogue. thomimetic effects (98,99). 5-IT, a positional AMT isomer
andasubstitutedphenethylamine,hasbeenmadeavailable
since 2012. It possesses both hallucinogenic and stimulant
SYNTHETICCOCAINESUBSTITUTES effects(98,99).
RTI-111 is a potent stimulant acting as an inhibitor of
serotonin,dopamineandnoradrenalinereuptake(94).RTI- GABA-A/BRECEPTORAGONISTS
121,developedinthe1990s,isapotent/long-lastingstimu-
lant acting as selective dopamine reuptake inhibitor (95). Currentlyusedinsomecountriestotreatnarcolepsyand
RTI-126(96)maypresentwithapotency5-foldhigherthan alcohol withdrawal (122), gamma-hydroxybutyric acid
cocaine(97).Whensnorted,thesecompoundsareassociat- (GHB, “liquid Ecstasy”) was developed as an anaesthetic
ed with alertness, euphoria, talkativeness, insomnia and some50yearsago.Itcanbeproducedinclandestinelabora-
prolongedresidualtension/anxiety(87). tories using a relatively simple synthesis with readily
available and inexpensive source materials. It is typically
ingestedorally.Gamma-butyrolactone(GBL)and1,4-buta-
NOVELTRYPTAMINEDERIVATIVES nediol,bothindustrialchemicals,arealsocurrentlyusedfor
theirGHB-likeeffects,withGBLbeingahighlipophilicity/
Synthetic tryptamines appeared on illicit drug markets highpotencyGHBpro-drug.
throughoutthe1990s(98),tobereplacedoverthelastfew GHB intake is associated with both increased central
years by cathinones, phenethylalamines and piperazines dopamine levels and activation of GABA-A/B receptors
(82,99). (123). GHB elimination half-life is 27 minutes, hence the
Nevertheless,noveltryptamines(e.g.,N-diallyl-5-methoxy- re-dosing risk (124). Euphoria and calmness are initially
tryptamine,5-MeO-DALT;alpha-methyltryptamine,AMT;5- observed after ingestion. A low/moderate oral dose of
methoxy-alpha-methyltryptamine,5-MeO-AMT;N,N-diallyl- 10mg/kg(0.75g)canproduceshort-termamnesia,hypoto-
4-hydroxytryptamine, 4-HO-DALT; 5-methoxy-diisopropyl- nia,loweringofinhibitionsandlibidoincrease.Higherdos-
tryptamine,5-MeO-DIPT;5-methoxy-N,N-dimethyltryptamine, agesleadtodrowsiness,nausea,vomiting,musclestiffness,
5-MeO-DMT;N,N-diethyltryptamine,DET;5-(2-aminopro- dizziness, confusion, delirium, hallucinations, convulsions
pyl)indole,5-IT)continuetoappearontheonlinedrugsce- andcardiopulmonarydepression.
nario(2,82,100,101). GHB is highly addictive (125), with its withdrawal syn-
Mostexogenoustryptaminesarepsychoactivehallucino- dromebeingcharacterizedbyinsomnia,muscularcramping,
gensfoundnaturally(102-106),notablyinDelospermaspe- tremorandanxiety(126).InitialUKdataindicatethatthere
ciesplants(dimethyltryptamine,DMT;5-MeO-DMT),hal- have been 159 GHB/GBL-associated fatalities reported
lucinogenic fungi (psilocin; 4-OH-DMT), and amphibians overthelasttwodecades.Mostdeaths(79%)wereaccidental
(bufotenin). Endogenous bufotenin and DMT have been andGHB/GBLalonewasimplicatedin37%ofcases(127).
17

## Page 4

BaclofenisaGABA-Bagonist(128)showingbothanxio- dissociation, depersonalization, psychotic experiences and
lyticandanalgesicpropertieswhilstexertingsomebeneficial out-of-body/neardeathexperiences(e.g.,the“K-hole”,150).
alcohol, cocaine and nicotine anti-craving effects (129- In the long term, tolerance, dependence, withdrawal signs
132).ItcanalsobeusedforGHB/GBLwithdrawal/detoxi- and flashbacks are described, with schizotypal symptoms
fication(133).Mosttypically,misuserspresentwithahis- and perceptual distortions possibly persisting after cessa-
tory of substance abuse/self-medication with other sub- tion(154).
stancesandstarttakinglargedosagesafterbeingregularly Approximatelyonethirdofpatientswithlong-termrecrea-
prescribedwithbaclofenformedicalreasons(134). tionalketamineusepresentwithbothurological(“kbladder”,
Although signs of toxicity may be identified with as e.g.,dysuria,suprapubicpain,haematuria,decreasedbladder
littleas100mgofbaclofen(135),misusersreporttheintake capacitance, abnormal bladder histology, hydronephrosis)
of higher dosages in order to achieve the desired effects, (155)andintestinal(“kcramps”)(153)problems.Highdos-
including euphoria, relaxation and anxiety obliterating/anti- ageself-administrationmaybeassociatedwithbothcardio-
depressant-likeeffects,similartothosereportedafterGHB vascularandrespiratorytoxicity.Numbness,muscleweak-
andpregabalinintake(80,136). nessandimpairedperceptioncanresultinfalls,traumaor
Several deaths after baclofen overdose have occurred burns.Riskshavealsoincludeddrowning,deathfromhypo-
(137).Theacuteintoxicationischaracterizedbyseverehy- thermiaduetolyingoutsideinwinter,trafficaccidentsand
potonia,delirium,sedation,respiratorydepression,cardiac becomingacrimevictim(47,150).
conduction abnormalities, and possibly coma. Baclofen Methoxetamine(MXE,“SpecialM”)hasrecentlyentered
shouldalwaysbewithdrawngradually(138).Commonpre- themarketasastructuralanalogueofketamineinorderto
sentingwithdrawalfeaturesaremuscularhyperactivity,hyper- elude legislative sanctions (149). It may be swallowed or
thermia, metabolic derangements, rhabdomyolysis, convul- insufflated or injected or used rectally or sublingually at a
sions and delirium, with issues similar to the serotonin dosagerangeof5-100mg(9,80,87,136).
syndrome(139). MXEpossesses NMDAreceptorantagonism,dopamine
Phenibut (“PB”) is being used in Russia and Latvia for releasing and serotonin transporter inhibiting activities
thetreatmentofanxiety/alcoholwithdrawalsymptomsand (153). Most users report long-lasting dissociative effects
as a nootropic (140). As a dietary supplement, it is freely (e.g.,the“M-hole”,156).Althoughhavingbeenmarketedas
available online. When misused, it is typically taken orally “bladderfriendly”,initialpreclinicalstudiesareareasonof
in dosages (e.g., 1-3 g) notably superior to the therapeutic clear concern (157), with cerebellar features and seizures
ones,thusleadingtoariskforoverdose.Atthesedosages,it beinguniqueto“specialM”intoxications(158).Anumber
acts as agonist at GABA-A/B receptors, whilst stimulating of analytically confirmed MXE-related fatalities have been
dopamine/serotoninneurotransmissionaswell(141,142). described(148).
Itsusemayrapidlyleadtodependence/tolerance(143), Diphenidine (DND) and methoxphenidine (MXP) are
with related withdrawal symptoms being managed with novellefetaminederivativesactingasNMDAreceptorantag-
baclofen (144). Withdrawal signs/symptoms may include onists(159),serotonintransporterinhibitors,dopamineago-
visual and auditory hallucinations, psychomotor agitation, nists,andopioidagonists(87).Theycanbeingestedorinsuf-
derealization,depersonalization,increasedlightandsound flatedorinjectedatadosagerangeof50-150mg,withadura-
sensitivity,musclepain/twitches,tachycardia,nausea,trem- tion of effects of 8-12 hours (87). Interestingly, a range of
orandinsomnia(145).Acuteintoxicationischaracterized serotonin syndrome signs/symptoms have been associated
by tachycardia, visual hallucinations, tremor, nausea and withDND/MXPhighdosageingestion(80,87,136).
vomiting,withthepossibleoccurrenceoftheserotoninsyn- Dextromethorphan (DXM) is an over-the-counter anti-
drome(146,147). tussive lacking strong mu-opioid agonist properties but
acting as an NMDA receptor antagonist (159) whilst pos-
sessing serotonin transporter inhibiting activities (160).
PHENCYCLIDINE-LIKEDISSOCIATIVEDRUGS Withlong-termDXMabuse,psychoticdisturbancescanbe
observed(8,9).AbruptDXMcessationhasbeenassociated
Dissociativedrugsarebothpopularandacauseofclinical withwithdrawalsymptoms(e.g.,vomiting,diarrhoea,myal-
concern(148-150).Ketaminehydrochloride(“specialK”)is gias, restlessness, night sweats, insomnia, anxiety, but also
ofwidespreaduseworldwide. hallucinations and flashbacks) (161). DXM high dosage
Ketamine is usually diverted from veterinary clinics, ingestionmaybeassociatedwithoccurrenceoftheseroto-
whereitisusedforsurgicalinterventions.Itshallucinogenic ninsyndrome(160).
effectsarerelatedtocentral5-HT2Aagonism(151),NMDA
receptor antagonism (152), and high affinity for mu/delta/
sigmaopioidreceptors(153). PIPERAZINES
When misused, ketamine can be injected or snorted or
smoked or administered rectally, in a dosage range of 25- Benzylpiperazine (BZP) was initially trialled as an anti-
300mg.Itspsychotropiceffectsincludereferentialthinking, depressantsome40yearsago,butneverenteredthemarket.
18 WorldPsychiatry14:1-February2015

## Page 5

Especiallyinthepast,itwasincludedin“fake”Ecstasytab- opioid-like withdrawal symptoms upon discontinuation. A
lets.Itisan5-HT2Areceptoragonist,whichexplainsitshal- fewrelatedfatalitieshavebeenreported(47).
lucinogeniceffectsathigherdoses. Pipermethysticum(“KavaKava”)isasocial/ceremonial
Piperazines have become popular to mimic Ecstasy drinkinmanySouthPacificIslands,withkavalactonesand
effects,withtherecentlyintroduced“Molly”beingtypically kavapyrones being its active constituents (8,9,119). Out of
anMDMA/piperazinecombination(162).Theireffectsare these,desmethoxy-yangoninisareversibleMAOI-B,ableto
similartothoseofamphetamine,butlessintense(8,9,162). increaseaswelldopaminelevelsinthenucleusaccumbens
Theiringestionistypicallyassociatedwithstimulanteffects, (166).KavainisaN-terminalacetyltransferase(NAT)inhib-
but at higher dosages hallucinations can be reported as well. itor, supposedly with serotonin reuptake inhibition and
Seizurescanoccurinasmanyasoneinfivepatientspresenting NMDAreceptoractivationproperties(167).Yangoninacts
with piperazine toxicity, with hyponatremia, serotonin syn- as a cannabinoid CB1 agonist (168). Kava roots are also
dromeandrenalfailurehavingbeendescribedaswell(162). availableinliquidform,tinctures,extractsandtablets.Kava
Meta-chlorophenylpiperazine(mCPP)isthemaintrazo- confers a rapid onset, long-term sedation (119). There are
done/nefazodonemetabolite.Itshighdosageingestioncan severalreportsofassociatedliverdamageorfailure(169).
produceeuphoria,hypertensionandtachycardia. AyahuascaisapsychedelicSouthAmericanbrew,tradi-
tionally made from Banisteriopsis caapi vine (containing
beta-carboline harmala alkaloids, possessing reversible
HERBS/PLANTS MAOI-A properties) and Psychotria viridis, a DMT-
containingplant(8,9,119).Beingmetabolizedbythediges-
Salviadivinorum(“Sally-D”)hasalonghistoryasadivi- tiveMAO,DMTispracticallyinactiveiftakenorally,unless
natory psychedelic. Its current use includes smoking or combined with a MAOI. Effects may last 2-6 hours, and
chewingthedriedleavescontainingsalvinorinAandB,both include intense visual hallucinations, euphoria, paranoid
k-opioid receptor agonists (163). At high dosages, time dis- ideationandentheogenicsensations,associatedwithvomit-
tortion, vivid imagery and empathogenic effects have been ingand/ordiarrhoea(8,9,119).
anecdotallyreported(80,87,136).Whensmoked,itsclinical Ibogaine is a hallucinogenic alkaloid extracted from the
effects occur within 20-60 seconds and last 5-15 minutes. root bark of the Western African shrub Tabernanthe iboga,
Its intake may be associated with perceptual disturbances, traditionally used as a sacrament (8,9,119). It is an 5-HT2A
psychosis, headache, irritability and anxiety (80,87,136). agonist, dopamine agonist, NMDA receptor antagonist and
Dependenceandtolerancehavenotbeenreported. k-opioidreceptoragonist(170).Itsingestionisassociatedwith
Sceletium tortuosum (“Kanna”) is a traditional Southern visualhallucinationsandentheogeniceffects,possiblyassoci-
Africa entheogen (164) currently available as extract, dried- atedwithataxia,nausea,vomitingandarrhythmias(171).
powderedherb,tincture,teabagsandseeds.Itmaybesnorted, A recent increase in online discussions relating to the
smoked, chewed or swallowed (80,87,136). Desired effects possible misuse of magnolols has been identified by our
include euphoria, reduction of tension, libido enhancement researchgroup(172).ThebarkextractofMagnoliaofficina-
andappetitesuppression.Themood-elevatingactionisdueto lis is typically used in traditional oriental medicine for the
theserotoninergicactivityofitsalkaloids(165),e.g.,mesembr- treatmentofinsomnia,anxietyandallergies(173).Honokiol
ine, mesembrenone, mesembrenol and tortuosamine. Com- and magnolol, the mainconstituents of its extracts, are both
mon side effects reported are hypertension, headache and weakcannabinoidCB2andGABA-Areceptoragonists(174).
nausea, associated with anxiety, irritability and insomnia. A Magnolol is then metabolized into its 20-fold more potent
serotonin syndrome can occur if Kanna is associated with metabolite tetrahydromagnolol, active at cannabinoid CB1/
selectiveserotoninreuptakeinhibitors(SSRIs)orMAOinhib- CB2 receptors (174). Cannabis- and benzodiazepine-like
itors(MAOIs)(80,87,136). effects (e.g., sedation, reduced attention and concentration,
Mitragyna speciosa (“Kratom”) is a tree native to some headache)arebeingreported(80,87,172).
Asian countries whose leaves contain mitragynine, mitra- Hydrangeapaniculata/Hortensiaisacommonornamental
phylline, 7-hydroxymitragynine and O-desmethyltramadol. plant.Itsmisusemaybeassociatedwitharangeofcannabis-
Mitragynine (“biak-biak”) is a partial agonist of the mu/ like effects, e.g., euphoria, sedation, confusion, dizziness and
deltaopioidreceptors.7-hydroxymitragynineisamu-opioid headache(80,87,136).Itmaybesmoked,oringestedincapsu-
agonist30-foldmorepotentthanmitragynine.Mitraphylline les,extracts,teasorsugarsyrup.
acts both on mu/delta opiate receptors and as an NMDA Datura stramonium is another common plant well
receptorantagonist(119).Kratommaybesmokedorbrewed knownforitsmind-alteringproperties(e.g.,hallucinations,
or ingested as an extract. Users report either an opiate-like delusions, bizarre behavior and euphoria) associated with
sedation, particularly at higher dosages, or a cocaine-like xerostomia, severe mydriasis/photophobia, confusion, dis-
stimulation at lower dosages (80,87,136). Other clinical orientation, tachycardia, and amnesia (8,9,80,87,119). Re-
effects include severe nausea and vomiting associated with lated fatal medullary paralysis,arrhythmias and cardiovas-
visualdisturbances.Regularusemayleadtodependenceand cularcollapseeventshavebeenreported(47).
19

## Page 6

Nauclea latifolia is a flowering, tramadol-containing, Vulnerable subjects (e.g., adolescents, inmates) may be par-
sub-Saharanplant(175),usedrecreationallytoobtainpain ticularlyatrisk(182).Reasonsforabuseofatypicalantipsy-
relief,sedationandanxiolyticeffects(80,87). choticsmayincludethedesireof“feelingmellow”(183).
Thereareanecdotalreportsofmisuseofvenlafaxine,par-
ticularlyincombinationwithothersubstances(80,87,136),
PRESCRIBEDPRODUCTS possibly related to the increase it produces in dopamine
neurotransmission(184,185),particularlyatthelevelofthe
Pregabalin is approved in Europe for the treatment of prefrontalcortex(186).
epilepsy/partialseizures,neuropathicpainandgeneralized Recentconcernsrelatingtoorphenadrine(ananticholin-
anxiety disorder. The molecule is however also often ergic drug) misuse have been reported (187). Similarly,
prescribed off-label for a range of psychiatric conditions, misuseoftropicamide(anophthalmicanticholinergiccom-
including bipolar disorder, alcohol/narcotic withdrawal pound producing short-acting mydriasis and cycloplegia)
statesandattention-deficit/hyperactivitydisorder.Inparal- has been recently described (188). When misused, tro-
lelwithincreasingprescribinglevels,agrowingblackmar- picamideistypicallyinjectedintravenously,oftenincombi-
ketiscurrentlybeingobserved(8,9,176,177). nation with other psychoactives. Tropicamide-related psy-
Potentbindingofpregabalinandgabapentinatthecalci- choactiveeffectsincludehallucinations,“openeyedreams”
um channel results in a reduction in the release of exci- and dysphoria, associated with slurred speech, persistent
tatorymolecules.Furthermore,theyarethoughttopossess mydriasis, hyperthermia, tremor, convulsions, psychomo-
GABA-mimeticpropertiesanddirect/indirecteffectsonthe toragitation,tachycardiaandsuicidalideation(188).
dopaminergic“reward”system(177).Overall,pregabalinis
characterized by higher potency, quicker absorption rates
andgreaterbioavailabilitythangabapentin(176). PERFORMANCEANDIMAGEENHANCINGDRUGS
Typicalmisusersofthesecompoundsareindividualswith
ahistoryofrecreationalpolydruguse.Arangeofexperiences Increasing consumption levels of substances known as
maybeassociatedwithgabapentinabuse,includingeupho- performance and image enhancing drugs (PIEDs) have
ria,improvedsociability,opiate-likesedationandpsychedel- beenrecorded(8,9,189).PIEDsaredrugs,nutrients,drinks,
iceffects(176).Similarly,pregabalinisconsideredan“ideal vegetable extracts or potions from a range of different
psychotropic drug” to achieve specific mindsets, including sources.
sedativeeffectsmixedwitheuphoriaanddissociation. Among image enhancers, there are increasing levels of
Misuseofpregabalin,atdosagesupto3-20timeshigher concern regarding the misuse of the slimming aid dinitro-
than the maximal dosage indicated (176), mostly seems to phenol(DNP),whoseintakehasbeenimplicatedinanum-
occur orally, but intravenous use, rectal “plugging” and ber of UK fatalities (47,190). DNP is offered online as a
smokinghavebeenreportedaswell.Afewdrugsarereport- metabolism booster to bodybuilders and dieters. Its inges-
edlymisusedincombinationwithpregabalinorgabapentin, tionmaybeassociatedwitheuphoria,energyincrease,nau-
including cannabis, alcohol, lysergic acid, amphetamine seaandheadache(8,9).
andGHB(176,177). Typicallyidentifiedindietarysupplements,1,3-dimethyl-
Phenazepam (“Zinnie”) is an old benzodiazepine, cur- amylamine(DMAA)intakeisassociatedwitheuphoriaand
rently prescribed in the Russian Federation for the treat- mild stimulant effects, together with hypertension, head-
mentofarangeofneurologicaldisordersaswellasforalco- ache, nausea, and vomiting (80,87,111). In parallel with
hol withdrawal/anxiety, and as a surgery premedication concerns about DMAA’s health risks, including deaths
(178).Easilyaccessibleonlineatlowprices,itisconsidered (191), new synthetic stimulants, including beta-methyl-
five times more powerful than diazepam (179). It can be phenylethylamine (BMPEA), N,alpha-diethylphenylethyl-
ingested,snortedorinjected,eitheronitsownorincombi- amine(DEPEA)andmorerecently1,3-dimethylbutylamine
nationwithother substances, with euphoriceffects having (DMBA)havebeenofferedtoonlinecustomerslookingfor
beendescribed(8,9).Reportedsideeffectsincludeamnesia, alternative “natural” dietary supplements. With DMBA,
dizziness, loss of coordination, drowsiness, blurred vision, effects such as restlessness, mood enhancement, increased
slurredspeechandataxia.Deathsbyrespiratoryarrestdue focus,nausea,flushingandtachycardiahavebeenreported
toitsmisuseincombinationwithothersedativeshavebeen (80,87,192).
reported(180). Melanotansynthetictanningagentsarelargelyavailable
Olanzapine is being anecdotally advised online as the online, aiming at promoting melanogenesis and hair-skin
“idealtripterminator”afterapsychedelicdrugbinge(181). pigmentation. Melanotan user groups include aesthetically
Themoleculeisself-prescribed,andforafewdaysonly,at driven women, body dysmorphics and male bodybuilders.
dailydosagesupto50mg/die. Sexual arousal, flushing, nausea, weight loss and immune
Quetiapine(“Qball”)issimilarlyanecdotallyconsidered responsealterationshavebeenreported(193,194).
to“comeoffthepsychedelictrip”(181),withtypicalmisus- A range of natural products available online, such as
ers being clients with a previous substance abuse history. those containing Tribulus terrestris, are becoming popular
20 WorldPsychiatry14:1-February2015

## Page 7

because oftheir alleged powerfulpro-testosterone,muscu- ever, previous studies from our group (4,176) have clearly
larstrengthenhancerformula.Bothincreasedsexualarous- suggested that an increase in online trafficking/debate
al (80,87) and psychotic episodes (associated with long- about a specific psychoactive drug typically precedes the
termingestion)(189)havebeendescribed. occurrenceofclinicalincidentsatthepopulationlevel.
Among cognitive enhancers, piracetam, aniracetam and Consumers of novel psychoactive substances may self-
centrophenoxinehavebeenreportedtobeabusedbyhealthy refer overnight to accident and emergency departments,
individuals with the hope to improve their performance in when concerned with acute medical or psychiatric prob-
studyandwork-relatedactivities(195).PiracetamisaGABA lems,withoutdisclosingtheirsubstanceintakeandshowing
derivative,originallymarketedin1971asanootropic(196), negativeresultsatthestandarddrugtests(8,9).Itisclearly
duetorestoredneurotransmissionandincreasedbrainoxy- difficulttodrawadetailedanduniversalmanagementplan
gen consumption(197). With the ingestionof high dosages tocopewiththebehaviouralandpsychopathologicaldistur-
of these substances, hallucinations and mood alterations bancesrelatedtotheintakeofthevirtuallyfewhundredsof
havebeenreported(80,136,196). substancescurrentlyavailable(8,9,162).
“Natural” sexual performance enhancers are advertised Giventhecomplexorunknownpharmacologyofthesub-
onlineas“safer”alternativestopharmaceuticalphosphodi- stancespossiblyingestedbytheclient,benzodiazepinesmay
esterase type 5 inhibitors. The most popular compounds be agents of choice (3). They may, however, need frequent
includeyohimbine,Maca,EpimediumandGinkgoBiloba. re-dosing/highdosagestoachieve adequate sedative effect,
Theiringestionhasbeenassociatedwithanxiety,irritability, andthismaybeaproblemifclientshaveco-ingestedalcohol
hypomanic reactions and inappropriate behaviour (80,87, (3). Where patients cannot be controlled with benzodiaze-
136,198). pinesalone,propofoland/orantipsychoticsmaybeconsid-
ered (8,9,162), although this may further contribute to the
acutetoxicityeffectsoftheabusedsubstances.
DISCUSSION Treatment of hyperthermia needs to be aggressively
planned, and this typically involves cooling measures and
The ever-increasing number of novel psychoactive sub- intravenousfluidadministrationforrhabdomyolysisconcern
stances emerging worldwide (2,8,9,101) and the parallel (3).Serotoninsyndromeismanagedusingbenzodiazepines
changesindrugscenariosrepresentachallengeforpsychia- and cyproheptadine (204). Inpatient admission, possibly to
try.Infact,theintakeofthesesubstancesistypicallyassoci- intensivecareunits,mayattimesbeneeded(8,9,162).
ated with the imbalance of a range of neurotransmitter The increasing levels of misuse of a range of medicinal
pathways/receptors, and consequently with the risk of products, otherwise representing a valuable asset in the
psychopathologicaldisturbances. pharmacological repertoire of psychiatry/addiction medi-
The occurrence of psychosis has been related to: a) cine(177),areareasonoffurtherconcern.Possiblesources
increased central dopamine levels (199), associated with ofthisacquisitionmayeitherbediversionofregularlypre-
theintakeofmostofthesesubstances,includingnovelpsy- scribedmedicinesoronline/“rogue”pharmacies(205).
chedelic phenethylamines, synthetic cathinones and 4,4’- Psychiatrists/physicianswhoconsiderprescribingapsy-
DMAR; b) cannabinoid CB1 receptor activation (200), choactive molecule possessing a potential for misuse (e.g.,
achievedwithsyntheticcannabimimetics;c)5-HT2Arecep- pregabalinorgabapentinforneurological/psychiatricdisor-
toractivation(201),reportedwithNBOMecompounds,lat- ders)shouldcarefullyevaluateapossibleprevioushistoryof
esttryptaminederivatives,lefetaminederivatives,DXMand drug abuse. Furthermore, they should be able to promptly
hallucinogenic plants; d) antagonist activity at NMDA identifysigns ofmisuse, andprovide assistanceintapering
receptors(202),describedwithphencyclidine-likedissocia- offtheindexmedication(177).
tives; and e) k-opioid receptor activation (203), typically The online market of novel psychoactive substances is
associatedwithSalviadivinorumintake. unfortunately developing far more rapidly than academic
Vulnerablesubjects,includingbothchildren/adolescents research (4). We believe that mental health professionals
and psychiatric patients, may be exposed to a plethora of needtobeawareofthepsychopathologicaleffectsofthese
“prodrug” webpages,whichprovidedirectdrugpurchase substances.Wehopethatthepresentpapermayrepresenta
opportunities and/or drug information (e.g.,description of usefulcontributioninthisrespect.
the drug effects, dose, chemistry and intake experiences).
Advancedlevelsofknowledgerelatedtonovelpsychoactive
substancesaretypicallyprovidedbydrugfora/blogcommu- Acknowledgement
nities’members(e.g.,the“e-psychonauts”,4).
Itisarguablyinappropriatetotrustinformationobtained ThispaperwassupportedinpartbygrantsoftheEuropean
online without independent verification, and only large Commission (Drug Prevention and Information Pro-
scale,adequatelycontrolledclinicalstudiescangiveaclear gramme2014-16,contractno.JUST/2013/DPIP/AG/4823,
indicationofdrugcharacteristicsandadverseeffects.How- EU-MADNESSproject).
21

## Page 8

References 20.WuritaA,HasegawaK,MinakataKetal.Alargeamountofnew
designer drug diphenidine coexisting with a synthetic cannabi-
noid 5-fluoro-AB-PINACA found in a dubious herbal product.
1.European Monitoring Centre for Drugs and Drug Addiction
ForensicToxicol2014;32:331-7.
(EMCDDA). European drug report 2014: trends and develop-
21.ChoiH,HeoS,ChoeSetal.Simultaneousanalysisofsynthetic
ments.Lisbon:EMCDDA,2014.
cannabinoids in the materials seized during drug trafficking
2.United Nations Office on Drugs and Crime (UNODC). Global
usingGC-MS.AnalBioanalChem2013;405:3919-63.
syntheticdrugsassessment.Vienna:UNODC,2014.
22.FattoreL,FrattaW.BeyondTHC:thenewgenerationofcanna-
3.Nelson ME, Bryant SM, Aks SE. Emerging drugs of abuse.
binoiddesignerdrugs.FrontBehavNeurosci2011;21:1-11.
EmergMedClinNorthAm2014;32:1-28.
23.BrentsLK,PratherPL.TheK2/spicephenomenon:emergence,
4.DelucaP,DaveyZ,CorazzaOetal.Identifyingemergingtrends
identification,legislationandmetaboliccharacterizationofsyn-
in recreational drug use; outcomes from the Psychonaut Web
theticcannabinoidsinherbalincenseproducts.DrugMetabRev
Mapping Project. Prog Neuropsychopharmacol Biol Psychiatry
2014;46:72-85.
2012;39:221-6.
24.PertweeRG.Receptorsandchannelstargetedbysyntheticcan-
5.European Monitoring Centre for Drugs and Drug Addiction
nabinoid receptor agonists and antagonists. Curr Med Chem
(EMCDDA). Hallucinogenic mushrooms: an emerging trend
2010;17:1360-81.
casestudy.Lisbon:EMCDDA,2006.
25.PapantiGD,OrsoliniL,FrancesconiGetal.‘Noids’;whatyou
6.PapantiD, Schifano F, Botteon G etal. ‘Spiceophrenia’: a sys-
(don’t) want to know about synthetic cannabinoids. Adv Dual
tematic overview of ‘Spice’-related psychopathological issues
Diagn2014;7:137-48.
andacasereport.HumPsychopharmacol2013;28:379-89.
26.Fisar Z. Inhibition of monoamine oxidase activity by cannabi-
7.SchifanoF.Drugs:treatmentandmanagement.In:GhodseAH,
noids. Naunyn Schmiedebergs Arch Pharmacol 2010;381:563-
HerrmanH, Maj Met al (eds).Substance abuse:evidenceand
72.
experience.Chichester:Wiley-Blackwell,2011:53-74.
27.MorganD,KondaboluK,KuipersAetal.Molecularandbehav-
8.SchifanoF.NPS:clinicalandpharmacologicalissues.Drugand ioralpharmacologyoftwonovelorally-active5HT2modulators:
AlcoholToday(inpress). potentialutilityasantipsychoticmedications.Neuropharmacol-
9.SchifanoF.Novelpsychoactivesubstancesalsoknownas‘legal ogy2013;72:274-81.
highs’. In: Davies SC (ed). Annual report of the Chief Medical 28.Halberstadt AL. Recent advances in the neuropsychopharma-
Officer2013.Publicmentalhealthpriorities:investingintheevi- cology of serotonergic hallucinogens. Behav Brain Res (in
dence.London:DepartmentofHealth,2014:259. press).
10.Lonati D, Buscaglia E, Papa P et al. MAM-2201 (analytically 29.Wells DL, Ott CA. The new marijuana. Ann Pharmacother
confirmed) intoxication after “synthacaine” consumption. Ann 2011;45:414-7.
EmergMed(inpress). 30.YipL,DartCR.Istheresomethingmoreaboutsyntheticcanna-
11.Aranda E, Sala E, Navarro M et al. Use of novel psychoactive binoids?ForensicToxicol2014;32:340-1.
substances (NPS): a description of a harm reduction center in 31.BoyerEW,ShannonM.Theserotoninsyndrome.NEnglJMed
Barcelona.ResAdvPsychiatry2014;1(Suppl.1):36. 2005;352:1112-20.
12.VandreyR,DunnKE,FryJAetal.Asurveystudytocharacterize 32.IsmailF.Importantfluorinateddrugsinexperimentalandclini-
use of Spice products (synthetic cannabinoids). Drug Alcohol caluse.JFluorChem2002;118:27-33.
Depend2012;120:238-41. 33.WilkinsonSM,BanisterSD,KassiouMetal.Bioisostericfluo-
13.Kikura-HanajiriR,UchiyamaN,KawamuraMetal.Changesin rineintheclandestinedesignofsyntheticcannabinoids.AustJ
theprevalenceofsyntheticcannabinoidsandcathinonederiva- Chem(inpress).
tivesinJapanuntilearly2012.ForensicToxicol2013;31:44-53. 34.Hermanns-Clausen M, Kneisel S, Szabo B et al. Acute toxicity
14.Ogata J, Uchiyama N, Kikura-Hanajiri R et al. DNA sequence due to the confirmed consumption of synthetic cannabinoids:
analysesofblendedherbalproductsincludingsyntheticcannabi- clinicalandlaboratoryfindings.Addiction2013;108:534-44.
noidsasdesignerdrugs.ForensicSciInt2013;227:33-41. 35.SpadernaM,AddyPH,D’SouzaDC.Spicingthingsup:synthet-
15.ParkY,LeeC,LeeHetal.Identificationofanewsyntheticcan- iccannabinoids.Psychopharmacology2013;228:525-40.
nabinoid in a herbal mixture: 1-butyl-3-(2-ethoxybenzoyl)in- 36.WinstockAR,BarrattMJ.The12-monthprevalenceandnature
dole.ForensicToxicol2013;31:187-96. ofadverseexperiencesresultinginemergencymedicalpresenta-
16.Uchiyama N, Kawamura M, Kikura-Hanajiri R et al. URB- tionsassociatedwiththeuseofsyntheticcannabinoidproducts.
754: anewclassofdesignerdrugand12syntheticcannabinoids HumPsychopharmacol2013;28:390-3.
detectedinillegalproducts.ForensicSciInt2013;227:21-32. 37.Freeman MJ, Rose DZ, Myers MA et al. Ischemic stroke after
17.UchiyamaN,ShimokawaY,MatsudaSetal.Twonewsynthetic useofthesyntheticmarijuana‘spice’.Neurology2013;81:2090-
cannabinoids,AM-2201benzimidazoleanalog(FUBIMINA)and 3.
(4-methylpiperazin-1-yl)(1-pentyl-1H-indol-3-yl)methanone(ME- 38.FreemanWD,JacksonvilleFL,LouhIK.“Spiceencephalopathy”.
PIRAPIM), and three phenethylamine derivatives, 25H-NBOMe Responseto“Ischemicstrokeafteruseofthesyntheticmarijua-
3,4,5-trimethoxybenzyl analog, 25B-NBOMe, and 2C-N-NBOMe, na‘spice’”.Neurology2014;81:2090-3.
identifiedinillegalproducts.ForensicToxicol2014;32:105-15. 39.MirA,ObafemiA,YoungAetal.Myocardialinfarctionassoci-
18.UchiyamaN,MatsudaS,KawamuraMetal.Twonew-typecan- atedwithuseofthesyntheticcannabinoidK2.Pediatrics2011;
nabimimeticquinolinylcarboxylates,QUPICandQUCHIC,two 128:e1622-7.
newcannabimimeticcarboxamidederivatives,ADB-FUBINACA 40.CentersforDiseaseControlandPrevention(CDC).Acutekid-
and ADBICA, and five synthetic cannabinoids detected with a neyinjuryassociatedwithsyntheticcannabinoiduse–multiple
thiophenederivativea-PVTandanopioidreceptoragonistAH- states,2012.MMWRMorbMortalWklyRep2012;62:93-8.
7921identifiedinillegalproducts.ForensicToxicol2013;31:223- 41.Saito T, Namera A, Miura N et al. A fatal case of MAM-2201
40. poisoning.ForensicToxicol2013;31:333-7.
19.DresenS,FerreirosN,PutzMetal.Monitoringofherbalmix- 42.Shanks KG, Dahn T, Terrell AR. Detection of JWH-018 and
turespotentiallycontainingsyntheticcannabinoidsaspsychoac- JWH-073 by UPLC-MS-MS in postmortem whole blood case-
tivecompounds.JMassSpectrom2010;45:1186-94. work.JAnalToxicol2012;36:145-52.
22 WorldPsychiatry14:1-February2015

## Page 9

43.SchaeferN,PetersB,BregelDetal.Afatalcaseinvolvingsever- 64.LoiB,ClaridgeH,GoodairCetal.Deathsofindividualsaged
alsyntheticcannabinoids.ToxichemKrimtech2013;80:248-51. 16-24intheUKafterusingmephedrone.HumPsychopharma-
44.SavasmanCM,PetersonDC,PietakBRetal.Twofatalitiesdue col(inpress).
totheuseofsyntheticcannabinoidsalone.Presentedatthe66th 65.WarrickBJ,WilsonJ,HedgeMetal.Lethalserotoninsyndrome
AnnualMeetingoftheAmericanAcademyofForensicSciences, aftermethyloneand butylone ingestion. J MedToxicol2012;8:
Seattle.Denver:PublicationPrintersInc.,2014:316. 65-8.
45.PattonAL, ChimalakondaKC, Cindy L et al. K2toxicity: fatal 66.SchifanoF,AlbaneseA,FergusSetal.Mephedrone(4-methyl-
case of psychiatric complications following AM2201 exposure. methcathinone;‘meowmeow’):chemical,pharmacologicaland
JForensicSci2013;58:1676-80. clinicalissues.Psychopharmacology2011;214:593-602.
46.Behonick G, Shanks KG, Firchau DJ et al. Four postmortem 67.McCann UD, Wong DF, Yokoi F et al. Reduced striatal dopa-
casereportswithquantitativedetectionofthesyntheticcannabi- minetransporterdensityintheabstinentmethamphetamineand
noid,5F-PB-22.JAnalToxicol2014;38:559-62. methcathinoneusers:evidencefrompositronemissiontomogra-
47.Corkery J, Claridge H, Loi B et al. Drug related deaths in the phy studies with [11C]WIN-35,428. J Neurosci 1998;18:8417-
UK.NPSADAnnualReport2013.London:InternationalCentre 22.
forDrugPolicy,St.George’sUniversityofLondon,2014. 68.AmbroseJB,BennettHD,LeeHSetal.Cerebralvasculopathy
48.ElliottS,EvansJ.A3-yearreviewofnewpsychoactivesubstan- after4-bromo-2,5-dimethoxyphenethylamineingestion.Neurol-
cesincasework.ForensicSciInt2014;243:55-60. ogist2010;16:199-202.
49.KronstrandR,RomanM,AnderssonMetal.Toxicologicalfind- 69.BosakA,LoVecchioF,LevineM.Recurrentseizuresandseroto-
ingsofsyntheticcannabinoidsinrecreationalusers.JAnalToxi- ninsyndromefollowing“2C-I”ingestion.JMedToxicol2013;9:
col2013;37:534-41. 196-8.
50.RosenbaumCD,ScalzoAJ,LongCetal.K2&Spiceabusers:a 70.TopeffJM,EllsworthH,WillhiteLAetal.Acaseseriesofsymp-
case series of clinical and laboratory findings. Presentedat the tomatic patients, including one fatality, following 2C-E expo-
North American Congress of Clinical Toxicology, Washington, sure.ClinToxicol2011;49:526.
September2011. 71.Schifano F, Corkery J, Naidoo V et al. Comparison between
51.WikstromM,ThelanderG,DahlgrenMetal.Anaccidentalfatal amphetamine/methylamphetamine and ecstasy (MDMA,
intoxicationwithmethoxetamine.JAnalToxicol2013;37:43-6. MDEA, MDA, 4-MTA) mortality data in the UK (1997-2007).
52.Gunderson EW, Haughey HM, Ait-Daoud N et al. ‘Spice’ and Neuropsychobiology2010;61:122-30.
‘K2’herbalhighs:acaseseriesandsystematicreviewoftheclini- 72.WinstockA,SchifanoF.Disordersrelatingtotheuseofecstasy,
caleffectsandbiopsychosocialimplicationsofsyntheticcanna- other‘partydrugs’andkhat.In:GelderM,AndreasenN,Lopez-
binoiduseinhumans.AmJAddiction2012;21:320-6. IborJJetal(eds).NewOxfordtextbookofpsychiatry.Oxford:
53.Nacca N, Vatti D, Sullivan R et al. The synthetic cannabinoid OxfordUniversityPress,2009:494-502.
withdrawalsyndrome.JAddictMed2013;7:296-8. 73.Corazza O, Schifano F, Farre` M et al. Designer drugs on the
54.New Zealand Ministry of Health. Revoked interim product Internet: a phenomenon out-of-control? Analysis of anecdotal
approvals.www.health.govt.nz. onlinereportsrelatingtothehallucinogenicdrugBromo-Drag-
onfly.CurrClinPharmacol2011;6:125-9.
55.RomingerA,CummingP,XiongGetal.Effectsofacutedetoxifi-
cation of the herbal blend ‘Spice Gold’ on dopamine D2/3 74.BersaniFS,CorazzaO,AlbanoGetal.25C-NBOMe:prelimi-
receptoravailability:a[18F]fallypridePETstudy.EurNeuropsy- narydataonpharmacology,psychoactiveeffectsandtoxicityof
chopharmacol2013;23:1606-10. a new potent and dangerous hallucinogenic drug. Biomed Res
Int(inpress).
56.Zimmermann US, Winkelmann PR, Pilhatsch M et al. With-
drawal phenomena and dependence syndrome after the con- 75.Davis FT, Brewster ME. A fatality involving U4Euh, a cyclic
sumptionof‘spicegold’.DtschArzteblInt2009;106:464-7. derivativeofphenylpropanolamine.JForensicSci1988;33:549.
57.DiFortiM,SallisH,AllegriFetal.Dailyuse,especiallyofhigh- 76.BrewsterME,DavisFT.AppearanceofAminorexasadesigner
potencycannabis,drivestheearlieronsetofpsychosisincanna- analogof4-methylaminorex.JForensicSci1991;36:587-92.
bisusers.SchizophrBull(inpress). 77.European Monitoring Centre for Drugs and Drug Addiction
58.CelofigaA,KoprivsekJ,KlavzJ.Useofsyntheticcannabinoids (EMCDDA). 4,4’-DMAR. Europol Joint Report on a new psy-
in patients with psychotic disorders: case series. J Dual Diagn choactivesubstance:4,4’-DMAR(4-methyl-5-(4-methylphenyl)-
2014;10:168-73. 4,5-dihydrooxazol-2-amine).Lisbon:EMCDDA,2014.
59.Oluwabusi OO, Lobach L, Akhtar U et al. Synthetic 78.BrandtSD,BaumannMH,PartillaJSetal.Characterizationofa
cannabinoid-induced psychosis: two adolescent cases. J Child
novelandpotentiallylethaldesignerdrug,(6)-cis-para-methyl-
AdolescPsychopharmacol2012;22:393-5. 4-methylaminorex (4,40-DMAR, or ‘Serotoni’). Drug Test Anal
60.Farre` M,PapaseitE,P(cid:2)erez-Man~a(cid:2)Cetal.Humanpharmacology 2014;7:684-95.
ofmephedrone:adose-findingpilotstudy.PresentedattheCol- 79.Chemrus.com.www.chemrus.com.
legeonProblemsofDrugDependenceMeeting,SanJuan,June 80.Drugs-forum.com.www.drugs-forum.com.
2014. 81.Serotoni.info.www.serotoni.info.
61.Schifano F, Corkery J, Ghodse AH. Suspected and confirmed 82.European Monitoring Centre for Drugs and Drug Addiction
fatalities associated with mephedrone (4-methylmethcathinone; (EUROPOL-EMCDDA).DangeroussyntheticdrugshittheEU
‘meowmeow’)intheUK.JClinPsychopharmacol2012;32:710- market.www.emcdda.europa.eu.
4. 83.BlickeFF,BurckhalterJH.a-thienylaminoalkanes.JAmChem
62.CorkeryJM,SchifanoF,GhodseAH.Mephedrone-relatedfatal- Soc1942;64:477.
ities in the United Kingdom: contextual, clinical and practical 84.AngelovD,O’BrienJ,KavanaghP.Thesynthesesof1-(2-thienyl)-
issues.In:GallelliL(ed).Pharmacology.Rijeka:InTech,2012: 2-(methylamino)propane(methiopropamine)andits3-thienyliso-
355-80. merforuseasreferencestandards.DrugTestAnal2011;5:145-9.
63.Corkery JM, Schifano F, Oyefeso A et al. ‘Bundle of fun’ or 85.Bouso ED, Gardner EA, O’Brien JE et al. Characterization of
‘bunch of problems’? Case series of khat-related deaths in the the pyrolysis products of methiopropamine. Drug Test Anal
UK.DrugsEducPrevPolicy2011;18:408-25. 2013;6:676-83.
23

## Page 10

86.IversenL,GibbonsS,TrebleRetal.Neurochemicalprofilesof 110.LessinAW,LongRF,ParkesMW.Centralstimulantactionsof
somenovelpsychoactivesubstances.EurJPharmacol2012;700: a-alkylsubstitutedtryptamineinmice.BrJPharmacol1965;24:
147-51. 49-67.
87.Bluelight.com.www.bluelight.com. 111.DarganPI,WoodDM.Novelpsychoactivesubstances:classifi-
88.TyersMB.Aclassificationofopiatereceptorsthatmediateanti- cation,pharmacologyandtoxicology.London:AcademicPress/
nociceptioninanimals.BrJPharmacol1980;69:503-12. Elsevier,2013.
89.UmemotoS,NagatsukaT,NakamuraH.N-(1,2-Diphenylethyl)- 112.Cozzi NV, Gopalakrishnan A, Anderson LL. Dimethyltrypta-
piperazine derivatives. Japanese patent, Jpn Tokkyo Koho, JP mine and other hallucinogenic tryptamines exhibit substrate
47049071(19721209),1972. behavior at the serotonin uptake transporter and the vesicle
monoaminetransporter.JNeuralTransm2009;116:1591-9.
90.Matsuno K, Senda T, Kobayashi T et al. Reduction of 4-
cyclohexyl-1- [(1R)-1,2-diphenylethyl]-piperazine-inducedmemo- 113.Fantegrossi WE, Murnane KS, Reissig CJ. The behavioural
ry impairment of passive avoidance performance by r1 receptor pharmacology of hallucinogens. Biochem Pharmacol 2008;75:
17-33.
agonistsinmice.MethFindExpClinPharmacol1998;20:575-80.
91.LindemanE,Ba€ckbergM,PersonneMetal.MT-45–enlivsfar- 114.NicholsDE.Hallucinogens.PharmacolTher2004;101:131-81.
115.FontanillaD,JohannessenM,HajipourARetal.Thehallucino-
ligochpotentielltototoxiskinternetdrog.Lakartidningen2014;
genN,N-dimethyltryptamine(DMT)isanendogenous sigma-1
111.pii:CZR4.
receptorregulator.Science2009;323:934-7.
92.Brayfield A. Tilidine hydrochloride. The complete drug refer-
116.Psychonautwiki.com.http://wiki.tripsit.me.
ence.Martindale:PharmaceuticalPress,2013.
117.Ray TS. Psychedelics and the human receptorome. PLoS One
93.KnausEE,WarrenBK,OndrusTA.Analgesicsubstitutedpiperi-
2010;5:e9019.
dylidene-2-sulfon(cyan)amidederivatives.USPatent4468403.CA
118.SogawaC,SogawaN,TagawaJetal.5-methoxy-N,N-diisopro-
1255680A1.CanadianPatents&DevelopmentLimited,1982.
pyltryptamine (Foxy), a selective and high affinity inhibitor of
94.Carroll FI, Gao Y, Rahman P et al. Synthesis, ligand binding,
serotonintransporter.ToxicolLett2007;170:75-82.
QSAR,andCoMFAstudyof3b-(p-substitutedphenyl)tropane-
119.UjvaryI.Psychoactivenaturalproducts:overviewofrecentdevel-
2b-carboxylicacidmethylesters.JMedChem1991;34:2719-25. opments.AnnIstSuperSanita(cid:3)2014;50:12-27.
95.Fleckenstein AE, Kopajtic TA, Boja JW et al. Highly potent 120.LyttleT,GoldsteinD,GartzJ.Bufo.Toadsandbufotenine:fact
cocaineanalogscauselong-lastingincreasesinlocomotoractivi- and fiction surrounding an alleged psychedelic. J Psychoactive
ty.EurJPharmacol1996;311:109-14. Drugs1996;28:267-90.
96.Carroll FI, Blough BE, Nie Z et al. Synthesis and monoamine 121.Wilcox J. Psychoactive properties of alpha-methyltryptamine:
transporter binding properties of 3-(3’,4’-disubstituted phenyl)- analysis from self reports of users. J Psychoactive Drugs 2012;
tropane-2-carboxylic acid methyl esters. J Med Chem 2005;21: 44:274-6.
2767-71. 122.Gallimberti L, Schifano F, Forza G et al. Clinical efficacy of
97.Clarke RL, Daum SJ, Gambino AJ et al. Compounds affecting gamma-hydroxybutyric acid in treatment of opiate withdrawal.
the central nervous system. 4. 3b-phenyltropane-2-carboxylic EurArchPsychiatryClinNeurosci1994;244:113-4.
estersandanalogs.JMedChem1973;16:1260-7. 123.BrennanR,VanHoutMC.Gamma-hydroxybutyrate(GHB):a
98.ShulginA,ShulginA.TiHKAL.Thecontinuation,1997.www. scoping review of pharmacology, toxicology, motives for use,
erowid.org. andusergroups.JPsychoactiveDrugs2014;46:243-51.
99.SandersB,LankenauSE,BloomJJetal.‘Researchchemicals’: 124.PalatiniP,TedeschiL,FrisonGetal.Dose-dependentabsorp-
tryptamineand phenylamineuseamonghigh-riskyouth.Subst tion and elimination of gamma-hydroxybutyric acid in healthy
UseMisuse2008;43:389-402. volunteers.EurJClinPharmacol1993;45:353-6.
100.ArunotayanunW,DalleyJW,HuangXPetal.Ananalysisofthe 125.European Monitoring Centre for Drugs and Drug Addiction
synthetictryptaminesAMTand5-MeO-DALT:emerging‘novel (EMCDDA). Report on the risk assessment of GHB in the
psychoactivedrugs’.BioorgMedChemLett2013;23:3411-5. framework of the joint action on new synthetic drugs. Lisbon:
EMCDDA,2002.
101.United Nations Office on Drugs and Crime (UNODC). www.
unodc.org. 126.GallowayGP,FrederickSL,StaggersF,Jr.Physicaldependence
onsodiumoxybate.Lancet1994;343:57.
102.Cimino G, De Stefano S. Chemistry of Mediterranean gorgo-
127.CorkeryJM,LoiB,ClaridgeHetal.Theevolutionandcharacter-
nians.SimpleindolederivativesfromParamuriceachamaeleon.
isticsofUKdeathsinvolvingGHBanditsanalogues.Presented
CompBiochemPhysiolCToxicolPharmacol1978;61:361-2.
at the3rdInternational ConferenceonNovel PsychoactiveSub-
103.DeKorne J. Ayahuasca analogs and plant-based tryptamines.
stances,Rome,May2014.RedAdvPsychiatry2014;1(Suppl.1):16.
Sacramento:TheEntheogenReview,1996.
128.Peng CT, Ger J, Yang CC et al. Prolonged severe withdrawal
104.CollinsM.Somenewpsychoactivesubstances:precursorchemi-
symptoms after acute-on-chronic baclofen overdose. J Toxicol
calsandsynthesis-drivenend-products.DrugTestAnal2011;3:
ClinToxicol1998;36:359-63.
404-16.
129.BreslowMF,FankhauserMP,PotterRLetal.Roleofgamma-
105.KoikeY,WadaK,KusanoGetal.Isolationofpsilocybinfrom
aminobutyric acid in antipanic drug efficacy. Am J Psychiatry
Psilocybeargentipesanditsdeterminationinspecimensofsome
1989;146:353-6.
mushrooms.Lloydia1981;44:362-5.
130.FranklinTR,HarperD,KampmanKetal.TheGABA agonist
B
106.MckennaDJ,TowersGHN.Biochemistryandpharmacologyof baclofenreducescigaretteconsumptioninapreliminarydouble-
tryptamines and beta-carbolines: a minireview. J Psychoactive blind placebo-controlled smoking reduction study. Drug Alco-
Drugs1984;16:347-58. holDepend2009;103:30-6.
107.GuichhaitRB.Biogenesisof5-methoxy-N,N-dimethyltryptamine 131.HaneyM, Hart CL, Foltin RW. Effects of baclofenon cocaine
inhumanpinealgland.JNeurochem1976;26:187-90. self-administration: opioid- and nonopioid-dependent volun-
108.BarkerSA,MontiJA,ChristianST.N,N-dimethyltryptamine:an teers.Neuropsychopharmacology2006;31:1814-21.
endogenoushallucinogen.IntRevNeurobiol1981;22:83-110. 132.Shoptaw S, Yang X, Rotheram-Fuller EJ et al. Randomized
109.Ka€rkka€inenJ,Ra€isa€inenM,NaukarinenHetal.Urinaryexcre- placebo-controlled trial of baclofen for cocaine dependence:
tion of free bufotenin by psychiatric patients. Biol Psychiatry preliminary effects for individuals with chronic patterns of
1988;24:441-6. cocaineuse.JClinPsychiatry2003;64:1440-8.
24 WorldPsychiatry14:1-February2015

## Page 11

133.SchepLJ,KnudsenK,SlaughterRJetal.Theclinicaltoxicology 158.European Monitoring Centre for Drugs and Drug Addiction
ofgamma-hydroxybutyrate,gamma-butyrolactoneand1,4-buta- (EMCDDA). Risk assessments. Methoxetamine. Report on the
nediol.ClinToxicol2012;50:458-70. riskassessmentof2-(3-methoxyphenyl)-2-(ethylamino)cyclohexa-
134.KapilV,GreenJL,LeLaitMCetal.Misuseoftheg-aminobuty- none(methoxetamine)intheframeworkoftheCouncilDecision
ric acid analogues baclofen, gabapentin and pregabalin in the onnewpsychoactivesubstances.Lisbon:EMCDDA,2014.
UK.BrJClinPharmacol2014;78:190-1. 159.Morris H, Wallach J. From PCP to MXE: a comprehensive
135.LeeTH,ChenSS,SuSLetal.Baclofenintoxication:reportof review of the non-medical use of dissociative drugs. DrugTest
four cases and review of the literature. Clin Neuropharmacol Anal2014;6:614-32.
1992;15:56-62. 160.Chyka PA, Erdman AR, Manoguerra AS et al. Dextromethor-
136.Erowid.org.www.erowid.org. phanpoisoning:anevidence-basedconsensusguidelineforout-
137.Haubenstock A, Hruby K, Jager U et al. Baclofen (Lioresal) of-hospitalmanagement.ClinToxicol2007;45:662-77.
intoxication report of four cases and review of the literature. 161.MillerSC.Dextromethorphanpsychosis,dependenceandphysi-
ClinToxicol1983;20:59-68. calwithdrawal.AddictBiol2005;10:325-7.
138.Coffey RJ, Edgar TS, Francisco GE et al. Abrupt withdrawal 162.Kersten BP, McLaughlin ME. Toxicology and management of
from intrathecal baclofen: recognition and management of a novelpsychoactivedrugs.JPharmPract(inpress).
potentially life-threatening syndrome. Arch Phys Med Rehabil 163.MunroTA,DuncanKK,XuWetal.Standardprotectinggroups
2002;83:735-41. createpotentandselectivekappaopioids:salvinorinBalkoxy-
139.MeythalerJM,RoperJF,BrunnerRC.Cyproheptadineforintra- methylethers.BioorgMedChem2008;16:1279-86.
thecal baclofen withdrawal. Arch Phys Med Rehabil 2003;84:
164.GerickeN,ViljoenAM.Sceletium–areviewupdate.JEthno-
638-42.
pharmacol2008;119:653-63.
140.HelanderA,Ba€ckbergM,BeckO.MT-45,anewpsychoactive
165.AbeN,AliZ,KhanIA.StructureofnovelalkaloidsfromScele-
substance associated with hearing loss and unconsciousness.
tiumtortuosum.PlantaMed2013;79:P34.
ClinToxicol2014;52:901-4.
166.BaumSS,HillR,RommelspacherH.Effectofkavaextractand
141.LapinI.Phenibut(beta-phenyl-GABA):atranquilizerandnoo-
individualkavapyronesonneurotransmitterlevelsinthenucle-
tropicdrug.CNSDrugRev2001;7:471-81.
usaccumbensofrats.ProgNeuropsychopharmacolBiolPsychi-
142.NurmandLB,OtterMI,VasarEE.Effectofstructuralanalogsof
atry1998;22:1105-20.
gamma-aminobutyric acid on serotonin- and dopaminergic 167.SeitzU,Schu€leA,GleitzJ.[3H]-monoamineuptakeinhibition
mechanisms.FarmakolToksikol1980;43:288-91.
propertiesofkavapyrones.PlantaMed1997;63:548-9.
143.ReDNetResearchGroup.Phenibutfullreport.London:King’s 168.LigrestiA,VillanoR,Allara(cid:3)Metal.Kavalactonesandtheendo-
CollegeLondon,InstituteofPsychiatry,2012.
cannabinoidsystem:theplant-derivedyangoninisanovelCB
144.Samokhvalov AV, Paton-Gay CL, Balchand K et al. Phenibut 1
receptorligand.PharmacolRes2012;66:163-9.
dependence.BMJCaseRep2013;2013.
145.Ho€gbergL,Szabo(cid:2)I,RuusaJ.Phenibutyieldedwithdrawalsymp- 169.SarrisJ,LaPorteE,SchweitzerI.Kava:acomprehensivereview
ofefficacy,safety,andpsychopharmacology.AustNZealJPsy-
tomsandpsychosis.Drugsfor cosmonauts– nowmarketedas
chiatry2011;45:27-35.
dietarysupplementsonline.Lakartidningen2013;110:825-7.
146.SchmittC,G(cid:2)eguC,SpadariMetal.UseofphenibutinFrance: 170.Bulling S, Schicker K, Zhang YW et al. The mechanistic basis
for noncompetitive ibogaine inhibition of serotonin and dopa-
reportoftwocases.Therapie2013;68:123-4.
minetransporters.JBiolChem2012;287:18524-34.
147.Ronn M. Serotonin syndrome or phenibut overdose: a case
171.VlaanderenL,MartialLC,FranssenEJetal.Cardiacarrestafter
study.JAmPharmAssoc2003;53:e151-70.
ibogaineingestion.ClinToxicol2014;52:642-3.
148.ChiappiniS,ClaridgeH,CorkeryJetal.SpecialMrelatedfatali-
tiesintheUK.ResAdvPsychiatry2014;1(Suppl.1):38. 172.BaccarinJ.EsisteunpotenzialedimisusodeiMagnololi?Ana-
lisiqualitativadeireportonline.MDdissertation,Universityof
149.CorazzaO,SchifanoF,SimonatoPetal.Phenomenonofnew
Padua,2014.
drugsontheInternet:thecaseofketaminederivativemethoxet-
amine.HumPsychopharmacol2012;27:145-9. 173.Lee WT, Lin MH, Lee EJ et al. Magnolol reduces glutamate-
150.SchifanoF,CorkeryJ,OyefesoAetal.Trappedinthe‘K-hole’; inducedneuronalexcitotoxicityandprotectsagainstpermanent
overviewofdeathsassociatedwithketaminemisuseintheUK focalcerebralischemiaupto4hours.PLoSOne2012;7:e39952.
(1993-2006).JClinPsychopharmacol2008;28:114-6. 174.RempelV,FuchsA,HinzSetal.Magnoliaextract,magnolol,and
151.Waelbers T, Polis I, Vermeire S et al. 5-HT2A receptors in the metabolites:activationofcannabinoidCB2receptorsandblock-
felinebrain:123I-5-I-R91150kineticsandtheinfluenceofketa- adeoftherelatedGPR55.ACSMedChemLett2012;4:41-5.
minemeasuredwithmicro-SPECT.JNuclMed2013;54:1428-33. 175.Ta€ıwe GS, Bum EN, Talla E et al. Nauclea latifolia Smith
152.Nishimura M, Sato K. Ketamine stereoselectively inhibits rat (Rubiaceae) exerts antinociceptive effects in neuropathic pain
dopaminetransporter.NeurosciLett1999;274:131-4. induced by chronic constriction injury of the sciatic nerve.
153.AdvisoryCouncilontheMisuseofDrugs(ACMD).Ketamine:a JEthnopharmacol2014;151:445-51.
reviewofuseandharm.London:ACMD,2013. 176.SchifanoF,D’OffiziS,PiccioneMetal.Istherearecreational
154.MorganCJ,MonaghanL,CurranHV.BeyondtheK-hole:a3- misuse potential for pregabalin? Analysis of anecdotal online
year longitudinal investigation of the cognitive and subjective reportsincomparisonwithrelatedgabapentinandclonazepam
effectsofketamineinrecreationaluserswhohavesubstantially data.PsychotherPsychosom2011;80:118-22.
reducedtheiruseofthedrug.Addiction2004;99:1450-61. 177.Schifano F. Misuse and abuse of pregabalin and gabapentin:
155.Luciano RL, Perazella MA. Nephrotoxic effects of designer causeforconcern?CNSDrugs2014;28:491-6.
drugs:syntheticisnotbetter!NatRevNephrol2014;10:314-24. 178.RafstedtK,Hult(cid:2)enP,BrusiuK.Phenazepamasadrugofabuse
156.Corazza O, Schifano F. Ketamine-induced ‘near-death experi- –highfrequencyofprolongedsymptoms.Presentedatthe29th
ence’statesinasampleof50misusers.SubstUseMisuse2010; International Congress of the European Association of Poison
45:916-24. CentersandClinicalToxicologists,Stockholm,May2009.Clin
157.DarganPI,TangHC,LiangWetal.Threemonthsofmethoxet- Toxicol2009;47:436-510.
amineadministrationisassociatedwithsignificantbladderand 179.JohnsonB.New“old”drug:phenazepam(fenazepam).ToxTalk
renaltoxicityinmice.ClinToxicol2014;52:176-80. (SOFT)2010;34:17-8.
25

## Page 12

180.Corkery J, Schifano F, Ghodse AH. Phenazepam abuse in the 193.Brennan R, Van Hout MC, Wells J. Heuristics of human
UK:anemergingproblemcausingseriousadversehealthprob- enhancement risk: a little chemical help? Int J Health Promot
lems,includingdeath.HumPsychopharmacol2012;27:254-61. Educ(inpress).
181.ValerianiG,CorazzaO,BersaniFSetal.Olanzapineastheide- 194.VanHoutMC,BrennanR.Anin-depthcaseexaminationofan
al ‘trip terminator’? Analysis of online reports relating to anti- exoticdancer’sexperienceofmelanotan.IntJDrugPolicy2014;
psychotics’ use and misuse following occurrence of novel psy- 25:444-50.
choactivesubstance-relatedpsychoticsymptoms.HumPsycho- 195.CorazzaO,BersaniFS,BrunoroRetal.Performanceandimage
pharmacol(inpress). enhancing drugs: the abuse of cognitive enhancer piracetam.
SubstUseMisuse(inpress).
182.Klein-Schwartz W, Schwartz EK, Anderson BD. Evaluation of
196.Winblad B. Piracetam: a review of pharmacological properties
quetiapine abuse and misuse reported to poison centers.
andclinicaluses.CNSDrugRev2005;11:169-82.
JAddictMed2014;8:195-8.
197.Jordaan B, Oliver DW, Dormehl IC et al. Cerebral blood flow
183.Malekshahi T, Tioleco N, Ahmed N et al. Misuse of atypical
effects of piracetam, pentifylline, and nicotinic acid in the
antipsychotics in conjunction with alcohol and other drugs of
baboon model compared with the known effect of acetazol-
abuse.JSubstAbuseTreat(inpress).
amide.Arzneimittelforschung1996;46:844-7.
184.ShangY,GibbsMA,MarekGJetal.Displacementofserotonin
198.Corazza O, Martinotti G, Santacroce R et al. Sexual enhance-
anddopaminetransportersbyvenlafaxineextendedreleasecap-
mentproductsforsaleonline:raisingawarenessofthepsycho-
suleatsteadystate:a[123I]2beta-carbomethoxy-3beta-(4-iodo-
activeeffectsofyohimbine,Maca,HornyGoatWeedandGink-
phenyl)-tropanesinglephotonemissioncomputedtomography
goBiloba.BioMedResInt(inpress).
imagingstudy.JClinPsychopharmacol2007;27:71-5.
199.Brisch R, Saniotis A, Wolf R et al. Corrigendum: The role of
185.Weikop P, Kehr J, Scheel-Kru€ger J. The role of alpha1- and dopamine in schizophrenia from a neurobiological and evolu-
alpha2-adrenoreceptors on venlafaxine-induced elevation of tionaryperspective:oldfashioned,butstillinvogue.FrontPsy-
extracellular serotonin, noradrenaline and dopamine levels in chiatry2014;5:110.
theratprefrontalcortexandhippocampus.JPsychopharmacol 200.Hajo(cid:2)sM,HoffmannWE,KocsisB.Activationofcannabinoid-1
2004;18:395-403. receptorsdisruptssensorygatingandneuronaloscillation:rele-
186.StahlSM.Essentialpsychopharmacology.Neuroscientificbasis vancetoschizophrenia.BiolPsychiatry2008;63:1075-83.
and pratical applications, 4th ed. Cambridge: Cambridge Uni- 201.SelvarajS,ArnoneD,CappaiAetal.Alterationsintheseroto-
versityPress,2013. nin system in schizophrenia: a systematic review and meta-
187.GallegosA.TheEUearlywarningsystem:NPS.Presentedatthe analysisofpostmortemandmolecularimagingstudies.Neurosci
16thWorldCongressofPsychiatry,Madrid,September2014. BiobehavRev2014;45:233-45.
202.Genius J, Geiger J, Do€lzer AL et al. Glutamatergic dysbalance
188.BersaniFS,CorazzaO,SimonatoPetal.Dropsofmadness?Rec-
andoxidativestressininvivoandinvitromodelsofpsychosis
reational misuse of Tropicamide collyrium: early warning alerts
basedonchronicNMDAreceptorantagonism.PLoSOne2013;
fromRussiaandItaly.GenHospPsychiatry2013;35:571-3.
8:e59395.
189.MinerviniL,AntonielliRomaniniF,SolmiMetal. Acutepsy-
203.RanganathanM,SchnakenbergA,SkosnikPDetal.Dose-relat-
chotic episode associated with the intake of a testosterone-
ed behavioral, subjective, endocrine, and psychophysiological
enhancerherbalmixturepurchasedonline.PsychotherPsycho-
effectsofthejopioidagonistSalvinorinAinhumans.BiolPsy-
som2012;81:248-9.
chiatry2012;72:871-9.
190.GrundlinghJ,DarganPI,El-ZanfalyMetal.2,4-dinitrophenol
204.Mugele J, Nanagas KA, Tormoehlen LM. Serotonin syndrome
(DNP): a weight loss agent with significant acute toxicity and
associated with MDPV use: a case report. Ann Emerg Med
riskofdeath.JMedToxicol2011;7:205-12.
2012;60:100-2.
191.Cohen PA. DMAA as a dietary ingredient. JAMA Intern Med 205.LittlejohnC,BaldacchinoA,SchifanoFetal.Internetpharma-
2012;173:1038-9. ciesandonlineprescriptiondrugsales:across-sectionalstudy.
192.Cohen PA, Travis JC, Venhuis BJ. A synthetic stimulant never Drugs–EducPrevPolic2005;12:75-80.
testedinhumans,1,3-dimethylbutylamine(DMBA),isidentified
inmultipledietarysupplements.DrugTestAnal(inpress). DOI10.1002/wps.20174
26 WorldPsychiatry14:1-February2015

